FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 862 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR New on NCI’s Websites for September 2022 September 21, 2022 Adding Pembrolizumab To Preoperative Radiotherapy and Surgery Improves DFS for Patients... December 2, 2024 Patients Diagnosed with Cancer During Pregnancy May Have Increased Risk of... April 27, 2023 Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced... June 2, 2025 Load more HOT NEWS Patritumab Deruxtecan Demonstrates a Manageable Safety Profile and Durable Efficacy in... FDA Grants Accelerated Approval to Asciminib for Newly Diagnosed Chronic Myeloid... A PET-based, pCR-adapted Chemotherapy De-escalation Strategy Associated with an Excellent 3-year... Dual-Function Virus Engineered to Kill Tumor Cells and Support Immune Cells
